George Church

Cache Raises Seed Financing to Advance its Biomolecule Storage Technologies

Retrieved on: 
Martedì, Maggio 7, 2024
Technology, Research, Genetics, Health Technology, Biotechnology, Health, Data Management, Other Science, Science, Pillar, Harvard University, University, Cancer, Cache, International Society, American College, Cell, Laboratory, AUC, Harvard Business School, University Health Network, Biological engineering, Genetic, Software, Biophysical environment, Area studies, Biochemistry, RNA, Doctor of Philosophy, University Medical Center, Pathology, San Francisco Bay Area, Intelligence, ACMG, Stanford University, George Church, Bioethics, Chemistry, Faculty, MIT, MBA, SBIR, Yale School of Management, Temperature, Ageing, National Science Foundation, Dicarboxylic acid, Biology, Medical genetics, Nucleation, Computer data storage

Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.

Key Points: 
  • Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.
  • The funds will help power R&D and support commercial development efforts and key partnerships to bring their solutions to market.
  • “Over the past three decades, sequencing technologies have evolved drastically.
  • It feels like every month, a new sequencing method is developed,” says Michael Becich, Cache CEO.

World-Renowned Ancient DNA Expert, HHMI Investigator, and MacArthur Award Winner Beth Shapiro, Ph.D., Joins Colossal as Chief Science Officer

Retrieved on: 
Martedì, Marzo 19, 2024
Environment, Research, Genetics, Environmental Issues, Environmental Health, Biotechnology, Health, Other Science, Science, Genomics, Gene, Executive Committee, National Geographic Explorer, Woolly mammoth, Cell, University, Pennsylvania State University, Television, Life, DNA, Stanford University, CRISPR, Ice, Vertebrate Genomes Project, Hologenomics, Genome, HHMI, Colossal Biosciences, Balliol College, Oxford, Howard Hughes Medical Institute, Ecology and Evolutionary Biology, CSO, Domestication, Natural history, National academy, American Academy, Biology, Searle, George Church, Multimedia, MacArthur Fellows Program, Hunting

Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.

Key Points: 
  • Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.
  • In this role, she will oversee the continued expansion of the company’s de-extinction and conservation science teams.
  • A MacArthur “Genius Grant” Award winner and National Geographic Explorer, Beth Shapiro is a pioneer in the scientific fields of ancient DNA and paleogenomics.
  • “She’s the author of inspiring books 'How to Clone a Mammoth' and 'Life as We Made It,' plus an HHMI and MacArthur Fellow.

EnPlusOne Biosciences to Address Advances in the Enzymatic Synthesis of RNA at the 11th Annual Oligo Networking Conference

Retrieved on: 
Lunedì, Marzo 4, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Innovation, Enzyme, Doctor of Philosophy, MIT, Harvard University, Conference, Outline of health sciences, Wyss, RNA, George Church, Engineering, Oligonucleotide, Harvard Medical School, Wyss Institute, Fine chemical

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.
  • The two-day event will feature speakers from companies across life sciences discussing opportunities and challenges associated with the use of oligonucleotides in R&D and manufacturing by biopharmaceutical companies.
  • Mr. Ahlstedt’s presentation will highlight recent technical developments, and upcoming milestones, on the company’s proprietary enzymatic RNA oligonucleotide synthesis technology, as part of the Innovation in Manufacturing session at the event.
  • This community, from the beginning, has been supportive of our mission to deliver sustainable RNA at scale.

Generation Lab Emerges from Stealth with Funding Round and Mission to Extend the Human Healthspan – Waitlist for Its Clinically Driven At-Home Aging Test + Personalized Aging Intervention Opens Today

Retrieved on: 
Martedì, Gennaio 30, 2024
Marker beacon, Jools' Annual Hootenanny, Ageing, Inflammation, SAN, Mortality, Genetics, Research, Regeneration, Disease, Conceptual model, Conditional sentence, George Church, University of California, Berkeley, Longevity, QR, Homeostasis, CDC, UC, Harvard Medical School, Risk, Reproduction, University, Health, Generation

The company works with clinicians who can recommend personalized interventions, and Generation Lab can measure the effectiveness of these over time.

Key Points: 
  • The company works with clinicians who can recommend personalized interventions, and Generation Lab can measure the effectiveness of these over time.
  • These diseases are a major cause of morbidity and mortality and place a significant burden on our healthcare system.
  • Moreover, the biological age is quantified by Generation Lab for each function of the body: inflammation, regeneration, homeostasis, reproduction, etc.
  • After subsequent Generation Lab tests, your clinician can review how effective each intervention was and its impact on your health and rate of aging.

Frontier Bio Leads Medical Innovation with "Lab-Grown" Blood Vessel Technology for Replacing Animal Testing

Retrieved on: 
Martedì, Ottobre 24, 2023
3D, Aneurysm, Small Business Innovation Research, SBIR, Rupture, Rabbit, George Church, Tissue engineering, Research, Tissue, Risk, SAN, Blood, Safety, Mayo Clinic, NSF, National Science Foundation, Medical device, 3D printing, Medical imaging

At present, vascular medical devices must be assessed for safety and performance using animal studies, prior to any testing in human subjects.

Key Points: 
  • At present, vascular medical devices must be assessed for safety and performance using animal studies, prior to any testing in human subjects.
  • By introducing lab-grown vessels, Frontier Bio is championing a future where reliance on such animal testing is significantly reduced, if not eliminated.
  • As proof-of-concept, working with Mayo Clinic, Frontier Bio created a tissue-engineered blood vessel with an aneurysm and deployed a vascular flow diverter device into it.
  • George Church, a renowned geneticist and advisor to Frontier Bio, commented, "Frontier Bio is doing more than just creating lab-grown human tissues.

EnPlusOne Biosciences to Attend and Present Poster at OTS Annual Meeting

Retrieved on: 
Venerdì, Ottobre 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Wyss Institute, Harvard–MIT Program in Health Sciences and Technology, MIT, OTS, Harvard Medical School, CSO, Manuscript, Engineering, Outline of health sciences, Therapy, Wyss Institute for Biologically Inspired Engineering, RNA, George Church, Doctor of Philosophy, Oligonucleotide, Enzyme, Harvard University, Poster, NTS Sessions 1–4, Wyss, Fine chemical

The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.

Key Points: 
  • The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.
  • The poster presentation is entitled “A Platform for Controlled Enzymatic Synthesis of RNA Oligonucleotides“ and will be delivered by Dominic Rainone, an Associate Scientist at EnPlusOne Biosciences, during Poster Session 1, which begins at 17:00 on October 23rd.
  • Additional technical data from this poster can also be found in EnPlusOne’s recent manuscript pre-print available online.
  • Likewise, we’ve been very strong supporters of OTS and its mission to bring the field of oligonucleotides to its full therapeutic potential.

GEORGE CHURCH, JULIE CLAUSS JOIN UNRAVEL BIOSCIENCES ADVISORY BOARD

Retrieved on: 
Giovedì, Settembre 14, 2023
CRISPR, Drug development, Organizational founder, Therapy, Ipsen, George Church, MBA, RNA, History, Advisory board, Organization, Master of Engineering, Patient, Personal Genome Project, Machine learning, Biology, Health, Pharmaceutical industry, Colossal, Ultragenyx, Sanofi, Editas Medicine

BOSTON, Sept. 14, 2023 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), a therapeutics company leveraging a machine-learning model of human health to advance drugs for complex diseases, today announced the addition of Prof. George Church and Ms. Julie Clauss to its Advisory Board.

Key Points: 
  • BOSTON, Sept. 14, 2023 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), a therapeutics company leveraging a machine-learning model of human health to advance drugs for complex diseases, today announced the addition of Prof. George Church and Ms. Julie Clauss to its Advisory Board.
  • George Church, Ph.D. is a renowned geneticist and entrepreneur, noted for his integration of new technology with novel scientific questions focused on improving health.
  • Julie Clauss, MEng, MS, MBA is an experienced global pharma executive with 17+ years of experience in senior operating roles.
  • Julie Clauss is a highly accomplished business leader with a remarkable history of driving revenue growth strategies and guiding organizations to realize their vision of improving patient care.

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023

Retrieved on: 
Giovedì, Agosto 10, 2023
Nebula, Mayo Clinic, CPT, Marketing, Internet, George Church, Science, Stella, Nebula Genomics, Patient, Whole genome sequencing, Hospital Insurance and Diagnostic Services Act, Three Months, Automation, HRSA, Heart, Therapy, Diagnosis, Hope, Research, Endoscopy, COVID-19 testing, CLIA, Corporation, Medicine, Genetic, Growth, Prophase, System, CDX, IND, Exercise, DNA, Operation Linebacker, Absorption, History, Genetics, Algorithm, FDM, Omicron, Negotiation, Genomics, Cold, Sale, Public expenditure, Genetic counseling, EBITDA, Food, Renewable energy, Pharmaceutical industry, Retail, Cryptocurrency, Tourism, Fine chemical, Vaccine, Microscope, Q2, COVID-19, Bosc

Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023. The Company announced that despite the slowdown in the Covid-19 testing business, and the significant ramp-up of its multiple growth-oriented subsidiaries, adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million in Q2 and that the Company enjoys robust net working capital of $40.2 million as of June 30, 2023.

Key Points: 
  • Company to hold a conference call Thursday, August 10, 2023, at 11:00 AM ET
    Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023.
  • Revenues grew greater than 100% year-over-year for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.
  • Three Months Ended June 30, 2023 as compared to the Three Months Ended June 30, 2022.
  • Diagnostic services costs for the three months ended June 30, 2023 were $0.6 million compared to $1.8 million for the three months ended June 30, 2022.

ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test

Retrieved on: 
Martedì, Marzo 7, 2023
DTC, Nebula, Harvard Medical School, Nanopore sequencing, Genomics, Genetics, Gene, CLIA, HIPPA, Knowledge, Research, George Church, Genome, WGS, Health, NGS, Prophase, DNA, Management, Online shopping, Vaccine

Garden City, NY, March 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc. (“Nebula”), has introduced its lowest ever standard price of $249.00 for its direct-to-consumer (DTC) whole genome sequencing (WGS) DNA test.

Key Points: 
  • Garden City, NY, March 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc. (“Nebula”), has introduced its lowest ever standard price of $249.00 for its direct-to-consumer (DTC) whole genome sequencing (WGS) DNA test.
  • “Our mission at Nebula is to usher in a new era of personal genomics by providing access to affordable and secure whole genome sequencing, and today’s announcement marks strong progress toward this goal,” continued Mr. Karkus.
  • Nebula also provides customers with access to over 300 personalized reports based on their genomic profile.
  • Dr. Church has pioneered the development of multiple DNA sequencing methods, including molecular multiplexing approaches that enable next generation sequencing (NGS) as well as nanopore sequencing.

Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal

Retrieved on: 
Mercoledì, Marzo 1, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pillar, Boehringer Ingelheim, Therapy, Alnylam Pharmaceuticals, DSM-IV codes, Immune system, Disease, Ageing, Drug development, Patient, Biology, Kendall Square, Machine learning, General partnership, HOPE, The Golden Ticket, George Church, Novo Nordisk, Vaccine, Thymus, Pharmaceutical industry, Pfizer

The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.

Key Points: 
  • The financing will be used to advance Thymmune’s lead product THY-100 into preclinical studies in immune system disorders caused by thymic deficiencies (such as children born without a thymus), which result in a lack of functional T cells.
  • The funding will also be used to develop its thymic cell engineering platform and expand into additional indications across areas of unmet clinical need in immunology.
  • The thymus is a critical organ in the immune system that regulates and develops T cells, which are essential for fighting infection and disease, along with mounting effective responses to vaccines.
  • Thymmune has also received funding via Wellcome Leap’s inaugural HOPE program, along with an NIH/NIAID Fast-Track SBIR.